1.9 C
New York
Tuesday, December 23, 2025

Reviva’s schizophrenia drug advances to second phase 3 trial following FDA recommendation


FDA recommends second phase 3 trial for Reviva’s schizophrenia drug

Related Articles

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles